2024
Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
Elkeraie A, Al-Ghamdi S, Abu-Alfa A, Alotaibi T, AlSaedi A, AlSuwaida A, Arici M, Ecder T, Ghnaimat M, Hafez M, Hassan M, Sqalli T. Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective. International Journal Of Nephrology And Renovascular Disease 2024, 17: 1-16. PMID: 38196830, PMCID: PMC10771977, DOI: 10.2147/ijnrd.s430532.Peer-Reviewed Original ResearchChronic kidney diseaseSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsDiabetes mellitusKidney diseaseType 2 diabetes mellitusMajor public health concernAldosterone system inhibitorsBetter clinical outcomesCause of deathPublic health concernNephrology referralCKD managementClinical outcomesSystem inhibitorsCardioprotective propertiesEarly initiationTreatment pathwaysConsensus recommendationsHigh riskPatientsBetter careHealth concernEarly detectionHypertension
2018
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Eckardt K, Bansal N, Coresh J, Evans M, Grams M, Herzog C, James M, Heerspink H, Pollock C, Stevens P, Tamura M, Tonelli M, Wheeler D, Winkelmayer W, Cheung M, Hemmelgarn B, Participants C, Abu-Alfa A, Anand S, Arici M, Ballew S, Block G, Burgos-Calderon R, Charytan D, Das-Gupta Z, Dwyer J, Fliser D, Froissart M, Gill J, Griffith K, Harris D, Huffman K, Inker L, Jager K, Jun M, Kalantar-Zadeh K, Kasiske B, Kovesdy C, Krane V, Lamb E, Lerma E, Levey A, Levin A, Mauro J, Nash D, Navaneethan S, O’Donoghue D, Obrador G, Pecoits-Filho R, Robinson B, Schäffner E, Segev D, Stengel B, Stenvinkel P, Tangri N, Tentori F, Tsukamoto Y, Turakhia M, Vazquez M, Wang A, Williams A. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International 2018, 93: 1281-1292. PMID: 29656903, PMCID: PMC5998808, DOI: 10.1016/j.kint.2018.02.006.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGlomerular filtration rateKidney replacement therapyCKD G4Kidney failureFiltration rateRisk factorsGlobal outcomeTraditional CVD risk factorsCKD Prognosis ConsortiumCVD risk factorsCardiovascular disease eventsPrognosis of patientsOptimal therapeutic strategyControversies ConferenceCohort studyCVD outcomesHeart failureVariable prognosisClinical outcomesTherapeutic challengeKidney diseasePrognostic valueReplacement therapyInternational expert groupPatient preferences
2004
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal Of Medicine 2004, 350: 1516-1525. PMID: 15071126, DOI: 10.1056/nejmoa031633.Peer-Reviewed Original ResearchConceptsParathyroid hormone levelsPrimary end pointSecondary hyperparathyroidismHormone levelsPlacebo groupCinacalcet groupLow parathyroid hormone levelsSerum calcium-phosphorus productIntact parathyroid hormone levelsEnd pointCalcium-phosphorus productEfficacy assessment phaseParathyroid hormone valuesPatients Receiving HemodialysisPlacebo-controlled trialPercentage of patientsAdverse clinical outcomesCalcium-phosphorus homeostasisCalcium-sensing receptorClinical outcomesVitamin DDaily dosesStandard treatmentHormone valuesCardiovascular disease